Cre-mediated deletion of exons 3 and 4 of the mouse Brca2 gene occurring speci®cally in mammary epithelial cells of conditional female mutants carrying a combination of loxP-modi®ed and null Brca2 alleles resulted in a high incidence (77%) of breast tumors that were often palpable and developed in one or more glands after long latency (time for median tumor-free survival of *1.4 years; total of 40 tumors in 20 animals). These invasive adenocarcinomas were histologically quite uniform, exhibiting predominantly a solid, nodular tumor pattern with very few variants, in striking contrast to the morphological heterogeneity of analogous Brca1-associated tumors. The karyotypes of tumor cells lacking Brca2 had various chromosomal aberrations and ranged from diploid to hypertetraploid, but this wide variability was incongruous with the histological appearance of carcinomas that was comparable between specimens. The implications of these observations in the context of models positing that Brca2 is involved in the maintenance of genomic stability are discussed. Oncogene (2001) 20, 3937 ± 3948.
Introduction
The human breast cancer susceptibility gene BRCA2 (reviewed by Welcsh et al., 2000; Scully and Livingston, 2000) consists of 27 exons encoding a nuclear protein of 3418 amino acids. BRCA2 lacks recognizable structural motifs and regions of similarity with other proteins, but contains eight internal repeats (BRC) of variable length (30 ± 80 amino acid residues) in the segment encoded by the large (*4.5 kb) exon 11 (Bork et al., 1996) . BRC repeats are also present in the homologous proteins of several other mammals (Bignell et al., 1997) , including the mouse Brca2 (3329 amino acids; 59% human-mouse homology). These repetitive elements appear to serve as binding sites for direct physical interaction with Rad51 (Wong et al., 1997; Chen et al., 1998b; Katagiri et al., 1998) , although the latter may also interact with the Cterminal region of Brca2 (Sharan et al., 1997; Mizuta et al., 1997) . Currently, very little information is available about BRCA2 interactions with additional eectors and few clues about its molecular/biochemical function exist. Nevertheless, a putative transactivation domain has been described in the region encoded by exon 3 that also binds to a BRCA2-phosphorylating protein kinase (Milner et al., 1997 (Milner et al., , 2000 , as well as an interaction of the region encoded by exon 10 with the P/CAF histone acetylatransferase (Fuks et al., 1998) . Thus, roles of BRCA2 in transcription and/or histone modi®cation with potential implications for chromatin remodeling are possible.
The Brca2 gene is widely expressed in embryonic and adult tissues (Rajan et al., 1997) . In mammary glands, expression is high early in pregnancy, declining later and reaching the lowest level during lactation and involution (Rajan et al., 1997) . Although Brca2 bears no structural similarity to Brca1, there is striking resemblance in the developmental regulation and expression pro®les of the two cognate genes (see, for example, Rajan et al., 1997) . Moreover, participation of the two proteins in a common pathway has been suggested from in vitro data (Chen et al., 1998a) . Additional analyses also demonstrated a BRCA1/ BRCA2 interaction, which, however, did not involve more than 2 ± 5% of the available amounts of each protein (Chen et al., 1998a) , and was not con®rmed by biochemical fractionations of protein extracts Bochar et al., 2000) . Still, an enduring hypothesis (see Chen et al., 1999; Scully and Livingston, 2000) , which is based on the interactions and colocalization of BRCA1, BRCA2 and Rad51 in the nucleus and is supported by recombination assays using mutant cell lines (see, for example, Moynahan et al., 2001) , posits that at least one of the physiological functions of the BRCA proteins is related to DNA repair and maintenance of genomic integrity.
Overall, there is currently only fragmented information about the potential functions of BRCA1/2, while the exact roles of their mutated versions in tumorigenesis continue to remain unknown. In this regard, mutant mouse models initially contributed very little in functional analyses, because the embryonic lethality of Brca1 and Brca2 nullizygotes precluded studies of phenotypic consequences in adult mice (reviewed by Brugarolas and Jacks, 1997; Bertwistle and Ashworth, 1998; Deng and Scott, 2000) . However, conditional mutagenesis (Xu et al., 1999) and the generation of hypomorphic mutants (Connor et al., 1997; Friedman et al., 1998; Ludwig et al., 2001) , as means of bypassing embryonic lethality, are enhancing successfully the capability of developing suitable mouse models of Brca1-or Brca2-associated tumorigenesis. Here, we describe our analysis of breast cancer development in mice, after successful application of conditional gene targeting of Brca2 in mammary glands using the cre/loxP site-speci®c recombination system (see Sauer, 1998; Rossant and McMahon, 1999) .
Results

Experimental design
Tissue-speci®c conditional mutagenesis requires crosses between Cre-producing and Cre-responding strains of mice. To drive cre expression in producer mice, we chose the promoter/enhancer elements of the Wap gene encoding the milk whey acidic protein that is expressed speci®cally in mammary epithelial cells during late pregnancy and lactation (Robinson et al., 1995) . Brca2 is expressed in the same cells (Rajan et al., 1997) . The expression speci®city of Wap regulatory elements is apparently superior to that of the MMTV LTR (see Wagner et al., 1997) , but the successful generation of Wap-driven transgenes is complicated by the fact that additional control sequences residing in intronic and 3' noncoding regions seem to be necessary for ecient expression, which can still achieve only low levels of transcripts in comparison with the endogenous locus (see, for example, Hadsell et al., 1996) . Therefore, we chose for our purposes a knock-in strategy (Figure 1a) .
To generate responder mice with a Brca2 segment anked by loxP sites (`¯oxed'), we sought, while maintaining functionality of the locus in the absence of Cre, to position the loxP sites as close as possible to the 5' end, so that if any peptide were produced after recombination it would be severely truncated. Based on these considerations, we rejected a plan to¯ank with inserted loxP sites exon 1, since it was unpredictable whether the promoter region would remain active. Conditional mutagenesis aiming to the eventual elimination of each of the exons 2, 3 or 4 individually was also unfavorable, because of the possibility of generating hypomorphic, rather than null mutations that would maintain the ability to produce modi®ed proteins with functional domains, for the following reasons. Deletion of exon 2 alone, which carries the ATG initiator, may have been ineective, because of the presence of an in-frame ATG in exon 3, whereas sole elimination of either exon 3 or exon 4 would have preserved an open reading frame, because of fortuitous compatibility of splice sites between exons 2 and 4 or 3 and 5. Therefore, in our targeting design, we selected to¯ank with loxP sites a region containing both exons 3 and 4, to achieve their simultaneous deletion by Cremediated recombination (Figure 1c ). In this scheme, even if exons 2 and 5 were spliced successfully, a frameshift would occur resulting in the appearance of a stop codon in exon 7. As a result, only the ®rst 22 amino acids of a 77-residue peptide that could be potentially produced would represent authentic Brca2 sequence.
Brca2 conditional mutagenesis in the mouse mammary gland epithelium
Using a knock-in approach in 129/Sv ES cells, we inserted a cre gene immediately downstream of the 5' noncoding region of the Wap gene (see Figure 1a ,b and Materials and methods). Chimeric males generated by injection of Wap cre/+ ES cells into host blastocysts were crossed with C57BL/6J females to obtain heterozygous transgenic progeny. Females in which the transgene was occasionally brought into homozygosity (Wap cre/cre ) did not exhibit any overt phenotype, while signi®cant undernourishment of their pups, if any, due to the absence of Wap from the maternal milk was not observed. The ecacy of transgenic cre activity was tested successfully in preliminary experiments using as a reporter a¯oxed Igf1r gene (encoding the type 1 IGF receptor; see Dietrich et al., 2000) . We showed that, in ®rst-time pregnant Igf1r¯o
x/+ /Wap cre/+ females sacri®ced on day 17.5 of gestation, 32+6% (n=3) of the Igf1r¯o x allele had been converted by Cre-mediated deletion to Igf1r
D¯ox in mammary glands (S Xuan et al., unpublished results) .
Heterozygous progeny carrying a Brca2 targeted allele with¯oxed exons 3 and 4 (see Figure 1c and Materials and methods) were derived using the same steps of the standard targeting procedure described above. The¯oxed allele was designated Brca2¯o (Figure 1d ). These homozygous conditional mutants were fully viable and fertile, demonstrating that the Brca2¯o x targeted allele remains transcriptionally active in the absence of Cre. To demonstrate that the¯oxed allele would respond to the action of Cre resulting in excision of the region containing exons 3 and 4, we crossed Brca2¯o x/+ conditional mutants with transgenic mice expressing cre under the control of a heat shock gene promoter that is activated during embryogenesis without applica-tion of an external stimulus (see Dietrich et al., 2000) . Tail DNA assays showed that Cre-mediated sitespeci®c recombination had occurred in the progeny to various degrees (Figure 1e . These tissue-speci®c compound nullizygotes (heterozygotes for two dierent Brca2 null alleles) would lack Brca2 functions in the breasts. It is known, however, that transcription of the endogenous Wap gene at a high level lasts only for a x/+ animals either lacking (lane 1) or carrying (lanes 2 ± 4) a cre transgene driven by a heat shock promoter (Hscre1; Dietrich et al., 2000) . Expression of the transgene during embryogenesis (without heat shock) resulted in complete (lane 2) or partial (lanes 3 and 4) Cre-mediated recombination generating a Brca2
D¯ox allele (7.1 kb BamHI fragment). (f) Southern analysis of DNA prepared from tails (lanes 1, 3 and 5) and mammary tumors (lanes 2, 4 and 6) of Brca2¯o x/7 /Wap cre/+ mice. Each pair of samples (lanes 1/2, 3/4 and 5/6) is from the same animal. Complete Cre-mediated DNA excision generating a Brca2 D¯ox allele has occurred in the tumors. The size of the BamHI fragment derived from a non-¯oxed allele (9.5 kb) is the same for a wildtype or null locus, because the mutation of the latter is an insertion of a neo cassette into the downstream exon 11 (see Ludwig et al., 1997) time period that includes the end of pregnancy and the duration of lactation (Robinson et al., 1995) . For this reason, it was important to assess whether cells with a Brca2 D¯ox/7 genotype (i.e. candidates for tumor development by clonal growth) would persist after gland involution (480% of the epithelial area is lost during involution; Walker et al., 1989) . Using Southern analysis, we demonstrated that there was retention of the Brca2
D¯ox allele at signi®cant levels in DNA prepared from involuted mammary glands of Brca2¯o x/7 /Wap cre/+ females about 3 weeks after weaning of the litter. In fact, after a second pregnancy, the amount of the Brca2
D¯ox allele was increased in comparison with the level detected in animals that had undergone only a single pregnancy (data not shown). It seems, therefore, that Cre-mediated deletion occurs and then persists in some fraction of the putative stem cell population, despite massive apoptotic loss of epithelial cells during involution.
Mammary tumorigenesis in the absence of Brca2
A cohort of 26 experimental female animals, 24 with a Brca2¯o monitored closely for mammary tumor development over a period of *20 months. Palpable tumors became ®rst detectable in the experimental females after a long latency period of *13 months. Tumor-bearing animals either died (two cases) or were sacri®ced when moribund. At the end of the period of observation, all control animals (average age 518 days; range 496 ± 519) had remained mammary tumor-free (one of them exhibited an ovarian cystadenoma, apparently unrelated to the mutation). In contrast, 20/26 (*77%) of the experimental animals had developed mammary tumors. The T 50 for tumor-free survival was *17 months ( Figure 2 ).
Upon autopsy of sacri®ced mice bearing palpable tumors, additional independent tumors of smaller size were observed in some cases (Figure 3a) . A total of 40 mammary carcinomas were identi®ed in the 20 carriers, 10 of which had single tumors, four carried four tumors each, two had three tumors and four had two tumors (Table 1) .
Histopathological analysis of tumors
The macroscopic appearance of each of the larger tumors was invariably nodular. These nodules were well-circumscribed and corresponded histologically to two characteristic microscopic patterns: solid carcinoma (see Figure 3f ) and adenoacanthoma (adenosquamous carcinoma; Figure 3l ). Moreover, a mixture of the two histological forms within the same tumor was observed in some cases, although one of the types tended to predominate (see Table 1 and Figure 3n ). Both tumor types were invasive and exhibited an expansile growth pattern. Normal parenchyma was not present within the tumor nodules, i.e. tumor cells did not intermingle with normal mammary tissue, except at the outer edges of each nodule (Figure 3h,i) . The parenchyma adjacent to the tumor borders did not appear to be proliferative and no in situ dysplastic process was detected either in normal areas of aected glands or in unaected breasts.
The tumors with adenoacanthomatous dierentiation were characterized by the presence of abundant keratinizing squamous epithelium forming keratin-®lled cysts that were adjacent to small glandular structures (Figure 3l ). Lymphoid aggregates at the margins of these tumors were noted.
The solid nodular tumors possessed a framework of small vessels supporting mostly solid sheets of cells ( Figure 3g , and right sides of panels h and i), but some compact cell clusters and small tubules present at the tumor edges were observed on occasion. Some of the larger tumors exhibited extensive areas of central necrosis, calci®cation and/or ®brosis. However, neither a desmoplastic response (i.e. ®broblast proliferation and increase of collagenous matrix) nor an in¯amma-tory reaction was detected in adjacent normal parenchyma. Whereas the larger tumors (41 cm diameter) were uniformly solid, the smaller ones exhibited some structural variability and included small glands and tubules. Such glandular growth was minimal in general, and was observed exclusively at the peripheral portion of the tumor nodule, although a single tumor exhibited a striking tubuloglandular growth pattern (Figure 3o) . Overall, the tumor cells had uniform appearance. They did not exhibit wellde®ned borders, were of moderate size and possessed a small amount of eosinophilic cytoplasm. Their nuclei were generally round to ovoid with coarsely granular chromatin and a single prominent nucleolus. With the exception of two cases of severe nuclear atypia, only mild nuclear pleomorphism was observed in most of the tumors. A combination of a signi®cant level of mitotic activity and cell necrosis was noted.
Further characterization of tumors
To con®rm that tumor development was a direct consequence of ablation of Brca2 function in the mammary epithelium, we performed Southern analysis of DNA extracted from randomly picked tumors and showed that the genotype of these specimens was Brca2
D¯ox/7 (see Figure 1f ; a low level of nonrecombined Brca2¯o x allele was detected in some specimens, presumably because of contamination with a small amount of normal tissue).
Next, we performed cytogenetic analysis, to ascertain the condition of chromosomes in the tumors. Not unexpectedly, metaphase spreads from primary cultures of cells derived from six randomly picked tumors revealed various degrees of aneuploidy associated with diverse structural aberrations ( Table 2 ). For example, the presence of large marker chromosomes was consistently observed in all specimens, while double minutes and chromosome fragments were seen frequently. Interestingly, however, no correlation was noted between the severity of cytogenetic abnormalities and tumor latency. In fact, the tumor cells from the oldest of the examined carriers had mostly maintained a diploid karyotype (Case 18; Table 2 ). Moreover, histopathologically identical tumors (Cases 4 and 18, for example; Table 2 and Figure 4 ) exhibited signi®cant cytogenetic dierences.
Two of the specimens examined cytogenetically were also included in a preliminary molecular sampling of tumor DNA for deletions or rearrangements. For this purpose, we used as a marker the Fhit gene that is encompassing a fragile site altered in murine cancer cell lines (Glover et al., 1998) , and examined by Southern analysis the condition of its sequence in the genomes of ®ve tumors. In humans, Fhit spans a large region (*1 Mb encoding only a 1.1 kb transcript) that undergoes deletions or translocations in many human cancers, including a very large fraction of breast tumors associated with a BRCA2 mutation (Ingvarsson et al., 1999) . Our results demonstrated that of ®ve Fhit DNA bands (BamHI digestion fragments) hybridizing to a coding region probe, only one was missing in one of the specimens, whereas in a second specimen a dierent band was not equimolar. In the remaining three tumors, however, which included cases exhibiting cytogenetic abnormalities (Cases 6 and 7; /Wap cre/cre animals. Immunostaining is indicated as positive (+), strongly positive (+++), weakly positive (+) or negative (7). When an immunophenotype was not determined, the space is left blank. ERa, estrogen receptor; PR, progesterone receptor the assayable portion of the Fhit locus DNA had remained intact (data not shown).
Using a set of speci®c antibodies, we also performed immunohistochemical analyses, to assay for the presence or absence of selected markers (Table 1) . It has been observed that, in contrast to BRCA1-linked human breast cancers that are mostly negative for estrogen and progesterone receptors (*80% ER 7 , PR 7 ), tumors associated with BRCA2 mutations do not dier in this respect from sporadic cancers and are ER 7 only in their minority (*30%), while PR negativity does not exceed a frequency of *50% (reviewed by Chappuis et al., 2000) . In mammary tumors developing in mice carrying a truncating Brca1 mutation eliminating the segment encoding the Cterminal half of the protein product (Brca1 tr/tr mutants; Ludwig et al., 2001) , the ER and PR status was variable. Thus, 5/10 tumors were ER 7 and 7/10 tumors were PR
7
. Although these numbers are small and do not allow us to derive ®rm conclusions, it is notable that the situation with Brca2-linked tumors was similar, except that the PR negativity was higher (15/ 30 tumors were ER 7 and 30/32 tumors were PR
). Thus, the steroid hormone receptor pro®les appear to dier between human and mouse tumors. On the other hand, the high frequency of neu negativity observed with human BRCA1-and BRCA2-associated breast cancers was analogous to the complete absence of neu immunoreactivity in corresponding mouse tumors (see Table 1 and Ludwig et al., 2001) . However, all the Brca1-and Brca2-linked mouse mammary carcinomas were positive for cyclin D1 immunostaining, whereas this is rare in cancers arising in BRCA1 or BRCA2 mutation carriers compared with control cancers (Osin et al., 1998; Armes et al., 1999) . Because embryonic ®broblasts derived from mice homozygous for truncating Brca2 mutations overexpress both p53 and its target p21
Waf1 (Connor et al., 1997; Patel et al., 1998) , these markers were also examined by immunostaining in Brca2-linked tumors (Table 1) . Although immunophenotyping cannot provide information about expression levels, the examined tumors were positive for p21
Waf1 without exception and also positive for p53 in their majority (16/23).
Based on the latter information, we used RT ± PCR to amplify the particular p53 sequences expressed in the unique or largest tumor specimens of Cases 1, 5, 6, 7 and 14 (Table 1) and then analysed the products by Tables 1 and  2 ). The cells in (a) were mostly hyperdiploid to tetraploid, whereas they were mostly diploid in (b), although a single large marker chromosome (LC) was noted. Additional structural aberrations, including double minutes (DM) and also acrocentric (AC) and dicentric (DC) chromosomes, were observed in (a) DNA sequencing, to ascertain whether any of the exons of the p53 gene was mutated. This analysis did not reveal any dierences from wild-type in the tumors of Cases 5 and 14. However, the following amino acid replacements due to point mutations were detected in the remaining tumors: R270S (CGT?AGT; Case 1), R155P (CGC?CCT; Case 6) and N342D (AAT? GAT; Case 7). The ®rst two of these changes, but not the third, have been previously observed in human tumors (corresponding residues 158 and 273 in the human p53 sequence; see p53 mutation database at http://p53.genome.ad.jp).
Discussion
Mammary tumor histopathology
Previously, histopathological analyses of mammary carcinomas induced in transgenic mice by particular oncogenes expressed in the mammary epithelium under the control of the MMTV LTR quite often revealed reproducible development of`signature tumors' (Cardi et al., 1991 (Cardi et al., , 2000 . Thus, activated neu, for example, caused the appearance of solid, nodular tumors (Muller et al., 1988) possessing cells with pleiomorphic nuclei and pink cytoplasm that were intermediate in size between the cells characterizing myc-induced carcinomas (large blue cells) or rasinduced carcinomas (small red cells). In contrast, a variety of architectural patterns were detected in breast tumors developed after conditional mutagenesis of Brca1 in mouse mammary glands (Xu et al., 1999) or in mutants homozygous for a hypomorphic Brca1 allele (Brca1 tr/tr ; Ludwig et al., 2001) . It was, therefore, unexpected to ®nd that the histological appearance of the tumors associated with ablation of Brca2 action in mammary glands represented only an extremely narrow spectrum of variants and that the predominating solid, nodular pattern (see Figure 3g and right sides of panels h and i) was virtually indistinguishable from that of neu-induced carcinomas. In fact, as assessed from histopathological reports in the literature (Muller et al., 1988; Cardi et al., 1991) and from our own sections (not shown) of several independent tumors developed in neu transgenic animals that we maintain (see Materials and methods), these carcinomas, similarly to the Brca2-associated tumors, also contain focal areas of glandular dierentiation within a predominantly nodular, solid mass. In contrast to neu-induced tumors, however, no metastases in the lung or other sites were observed in the Brca2 cases that we have studied.
Because of low expression of neu in normal mammary glands, the cognate protein remains undetectable by immunohistochemical methods (DiGiovanna et al., 1998) . In contrast, tumor-inducing neu transgenes are usually expressed in carcinoma cells at levels 10 ± 50-fold higher than normal (Guy et al., 1992) . Clearly, therefore, the negative immunostaining for neu that we encountered in all of the examined Brca2-associated tumors (Table 1) indicated that no upregulation or ampli®cation of neu occurred in the course of tumorigenesis, despite a provocative histopathological similarity to neu-induced carcinomas.
It is thought that a histologically detectable premalignant stage is recognizable in the form of HAN (hyperplastic alveolar nodules) that can progress to DCIS (ductal carcinoma in situ; see Medina, 1996; Shoker and Sloane, 1999) . This view is not inconsistent with our observations. In fact, HAN associated with lobular neoplasia or with focal invasion was detected twice (Figure 3b,c) , while in another case (Figure 3d ) a HAN was colocalized with a DCIS and with an adenoacanthoma. Moreover, if a DCIS was not found in isolation (Case 13 was an example of a solitary DCIS; Table 1 ), it was associated either with an adenoacanthoma (Case 15) or with a solid tumor (Case 5a; see Figure 3k ). On the basis of these observations, we tentatively propose the following scheme for the development of mouse mammary tumors associated with absence of Brca2 function. A HAN gives rise to a DCIS that evolves into a solid carcinoma. The latter, in addition to its predominant solid form, has a few phenotypic variants, including adenoacanthoma, cribriform carcinoma (with fenestrations and recognizable glandular elements) or carcinoma with sarcomatous appearance. On occasion, progressive stages of the putative process described by our model can coexist in the same tumor (see Cases 4, 8 and 16) .
Tumor pathogenesis in the absence of Brca2
Although BRCA1 and BRCA2 could participate in the same pathway (Ludwig et al., 1997; Chen et al., 1998a; Scully and Livingston, 2000) , signi®cantly dierent groups of genes are expressed in breast cancers of patients with BRCA1 and BRCA2 mutations (Hedenfalk et al., 2001) . Analogous transcriptional pro®ling results using microarrays and further comparative analyses, including examination of potential genetic background-dependent eects, are required to reach unequivocal conclusions concerning Brca1-and Brca2-associated mammary tumors in mice. Nevertheless, a comparison of histopathological patterns of carcinomas developed after mammary gland-speci®c mutagenesis of Brca1 and Brca2 (Xu et al., 1999 and this report) indicated the presence of signi®cant structural dissimilarities. In conditional Brca1 mutants (ages 10 ± 13 months), ®ve microscopic and histopathologically diverse mammary tumors were observed that were developed with relatively low incidence (*22%) in females carrying MMTV-cre or WAP-cre transgenes (Xu et al., 1999) . Although the Brca2-associated tumors that we have studied also appeared after a long latency period, their incidence was much higher (77%), their sizes were signi®cantly larger and their histological patterns, although not exactly identical, were quite uniform. Thus, dierent animals or dierent breasts in the same animal developed independently invasive tumors with a predominating solid, nodular form that possibly evolved into a few variants, including a pattern of adenoacanthomatous metaplasia. Although adenosquamous carcinomas developing in the breast or in other organs are rarely observed in humans (see, for example, Denley et al., 2000) , it is interesting to note that independent molecular analyses of lung tumors have suggested that the squamous and adenocarcinomatous components had originated from the same cell (Niho et al., 1999; Kanazawa et al., 2000) .
The long tumor latencies observed and the histopathological analysis of breast carcinomas, which turned out to be relatively uniform in appearance, cannot be easily accommodated in a model postulating that, because of an apparent involvement of Brca2 in DNA repair processes (see Scully and Livingston, 2000) , ablation of its function contributes to tumorigenesis by promoting genomic instability. Had that been the case, a precancerous cell that was somehow able to survive apoptosis and had acquired deregulated growth properties would be further promoted on its way towards malignancy through a combinatorial engagement of deranged pathways by the acceleration of mutagenic events provoked by the early absence of Brca2-mediated DNA repair occurring after the ®rst pregnancy. These events, however, because of their stochastic character, would have involved the derangement and opportunistic recruitment of variable ®tting pathways whose participation would have resulted unpredictably in the development of tumors with histologically heterogeneous patterns. The rationale is that pathological features re¯ect drastic alterations in cellular constituents that are not expected to acquire by serendipity strong morphological similarities in unrelated cases, as they involve and change the properties of cytoskeletal elements or the cell membrane introducing changes in cell shape, nuclear size, adhesion traits etc. Moreover, beyond the cellular level, the intrinsic architectural pattern of a tumor, its histotypic dierentiation and also its relationship with the surrounding normal tissue acquire distinctive features. On the premise then that histopathology re¯ects pathogenesis (see Cardi et al., 1991) , we think that the obligatory predictions of an instability model do not appear to be compatible with the virtually deterministic character in the appearance of the predominantly solid, nodular tumor pattern that we have observed. It is notable in this regard that the cytogenetic analysis of tumor cells, although preliminary and limited in scope, also did not provide at this stage support for the view that chromosomal instability is causally involved in tumorigenesis. The detected karyotypic aberrations were in accord with the usually, but not universally observed aneuploidy of tumors (see Pihan and Doxsey, 1999) . Importantly, however, the variability in chromosome numbers and structural defects between tumors were incongruent with the uniformity of their histological forms. A remarkable example, in this regard, was provided by two histologically identical tumors, one of which exhibited a preponderance of diploid cells (Case 18; Table 2), while the cells of the other (Case 4) were almost exclusively hyperdiploid to tetraploid. Similar future observations from more detailed cytogenetic data could possibly provide, in conjunction with molecular analyses, more ®rm support to the notion that instability may be a consequence, and perhaps an opportunistic participant in progression, rather than a true cause of tumor development. It is notable that the ploidy of examined human BRCA2-linked tumors was variable (*30% were diploid and *70% aneuploid; Tirkkonen et al., 1997; Gretarsdottir et al., 1998; Agnarsson et al., 1998) .
Regardless of the open issue of genomic instability that will continue to be debated for some time to come, the striking histopathological dierence between Brca1-and Brca2-associated tumors requires comment. It could be argued that the Brca1 ablation (Xu et al., 1999) , which participates in the development of heterogeneous tumors, is a component that ®ts a much wider set of variably assorted tumorigenic pathways than the absence of Brca2, which is restricted in its potential and destined to participate in one or very few combinations resulting in tumors with uniform appearance. An alternative and perhaps better hypothesis is that, despite their apparent similarities that could re¯ect some overlapping functions, the mutated forms of Brca1 or Brca2 might participate quite dierently in tumor development, with the Brca2-elicited lesion(s) channelizing the actions of its tumorigenic partners towards the in¯exible occurrence of particular downstream events. If correct, this view would explain why the ablation of Brca2 function exhibits in the mammary epithelium a behavior that is, at least morphologically, analogous to that of an overexpressed dominant oncogene.
The appearance of Brca2`signature' adenocarcinomas in mice suggests that it may be feasible to also correlate particular tumor phenotypes with de®ned molecular lesions in other cases, including human neoplasms. However, a more re®ned, than usual, analysis is required when dealing with multidomain proteins like BRCA1/2. Because dierent segments apparently interact with dierent eectors, the particular involvement of tumorigenic pathways in each case could depend on variable leftover functions and could dier in tumor phenotype from the consequences of truly null mutations. Potentially, such molecular cartography' of tumor patterns may provide signi®cant clues about severity, clinical course and likelihood of metastases and thereby guide therapeutic regimes.
Materials and methods
Gene targeting
Targeting vectors (Figure 1a ,c) were constructed in several steps from subcloned fragments of overlapping l phage clones isolated from a genomic 129/Sv library and included a diphtheria toxin A gene cassette that was added as a negative selection marker against random integration (Yagi et al., 1990) .
The ®nal construct used to knock-in a cre gene into the Wap locus (Figure 1a) consisted of a 3.1 kb DNA fragment, extending between a XhoI site (present at a distance of *0.4 kb upstream from exon 1 of the Wap gene) and a BamHI site in exon 4, which was interrupted by an insert placed into a unique KpnI site (present in exon 1 immediately upstream of the Wap ATG; position 2419, GenBank Accession No. U38816). The insert consisted of a modi®ed cre sequence (from plasmid pMC-Cre; Gu et al., 1993) linked in tandem to the neomycin resistance marker (neo) under the control of the Pgk gene promoter. The cre gene possessed an aminoterminal SV40 nuclear localization signal, an ATG initiator placed in eukaryotic (Kozak) translational context and its own termination codon.
The targeting construct used to generate a¯oxed Brca2 allele (Figure 1c) consisted of a 5' genomic fragment (2.8 kb) from a NotI site (initially in the phage polylinker) to an EcoRI site (located in intron sequence *0.4 kb upstream from exon 3), a loxP site connected to a Pgk-neo cassette (*2 kb, with a transcriptional orientation opposite to that of Brca2), and a 3' Brca2 fragment (4.4 kb) from the aforementioned EcoRI to a SalI site (initially in the phage polylinker), which contained exons 3 ± 7 and carried a loxP site inserted in the intron between exons 4 and 5.
For targeting, linearized vector was introduced into W9.5 ES cells by electroporation and, after drug selection, DNA of resistant clones was analysed by Southern blotting using in each case appropriate probes (see Figure 1a ,c). Male chimeras were generated by standard methods and used in a breeding program described in detail in Results.
MMTV-neu transgenic mice developing rapidly mammary tumors (Muller et al., 1988) , which were analysed histologically for comparison purposes, were kindly provided by P Leder.
DNA and RNA analyses
For genotyping by Southern analysis (for details, see Figure  1 ), DNA was prepared from tails or mammary tumors of mice. To examine whether mutations of p53 had occurred in tumors, we performed RT ± PCR using total RNA templates and the primers 5'-gggaattcATGACTGCCATGGAGGAGT-CACAG-3' (forward) and 5'-ggggatccTCAGTCTGAGT-CAGGCCCCACTTTC-3' (reverse), to amplify the entire p53 coding region. Cloned ampli®cation products were then evaluated by DNA sequencing of overlapping shorter regions using combinations of external (vector) and internal primers.
Cytogenetic analysis
Tumor specimens were dissociated with collagenase and primary cultures of cells were grown for a short time in complete RPMI medium supplemented with insulin-transferrin-sodium selenate. Metaphases were prepared from 3 ± 10-day old primary cultures by using standard methods. Giemsastained or G-banded metaphases were analysed to score for numerical and structural abnormalities.
Histological analysis
Mice exhibiting overt pathological signs were sacri®ced and underwent autopsy. All major organs and any tumors identi®ed were dissected, ®xed overnight in 10% buered formalin and then dehydrated and embedded in paran. Paran blocks were sectioned at 5 mm and stained with hematoxylin and eosin. Immunophenotyping was performed with primary antibodies against estrogen receptor, progesterone receptor and p21 waf1 (Santa Cruz Biotechnology); c-neu and p53 (Oncogene Research Products); cyclin D1 (Novocastra Laboratories); cytokeratin (Chemicon); and vimentin (Research Diagnostics). Sections were then incubated with biotinylated secondary antibodies of appropriate speci®city and processed for immunostaining using avidin-biotin peroxidase and diaminobenzidine.
Statistical analysis
Survival time of mice was measured from the date of birth until the date of death or sacri®ce. Kaplan ± Meier cumulative tumor-free survival curves were plotted and compared pairwise by standard statistical rank tests using StatView software.
